Molecular metastases in stage I pancreatic cancer: Improved survival with adjuvant chemoradiation

Michael J. Demeure, Kara M. Doffek, Richard A. Komorowski, Philip N. Redlich, Yong Ran Zhu, Beth A. Erickson, Paul S. Ritch, Henry A. Pitt, Stuart D. Wilson

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Background. Reports of improved survival rates for patients with resected adenocarcinoma of the pancreas coincide with the adoption of adjuvant chemoradiation protocols. The impact of nodal micrometastases demonstrated by molecular assays and adjuvant therapy on survival of patients with stage I pancreatic cancer has not been adequately assessed. Methods. A retrospective analysis of postoperative chemoradiation on survival in 61 patients undergoing resection of pancreatic adenocarcinomas from 1984 to 1997 was performed. Archival tumors and regional nodes from 25 patients with stage I cancers were tested for a Kiras oncogene mutation using polymerase chain reaction and analysis for restriction fragment length polymorphisms (PCR/RFLP). Results. Adjuvant chemoradiation was associated with improved survival for stage I (P <.01), but not stage III, disease. Seventeen (68%) of 25 patients with stage I disease tested had evidence of mutant Kiras in one or more regional nodes. Survival did not differ for patients with molecular micrometastases. Six of 17 (35%) patients with micrometastases received adjuvant chemoradiation and had improved survival (P < .05). Conclusions. The majority of patients with stage I pancreatic cancer have PCR/RFLP evidence of lymph node micrometastases. Adjuvant chemoradiation improves survival in these patients by treating micrometastases not detected by histology. Adjuvant chemoradiation should be used for patients with stage I pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)663-669
Number of pages7
Issue number4
StatePublished - 1998

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Molecular metastases in stage I pancreatic cancer: Improved survival with adjuvant chemoradiation'. Together they form a unique fingerprint.

Cite this